Peptides in Mental Health: A New Frontier
Nootropics like NAD+, Selank, and GLP-1 agonists offer alternative options beyond traditional pharmaceutical treatments for mental health issues.
Costco to sell Ozempic and Wegovy at a large discount
Costco to sell Ozempic and Wegovy at a large discount
Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena
GLP-1RAs and Cancer Risk: Can This Trial Emulate Reality?
Jason L. Oke, MSc, DPhil, digs into what a recent target trial-emulation study really tells us about GLP-1 RAs and cancer prevention. Medscape Oncology
MT1-MMP Inhibition Restores Some Lost Cognitive Function in Both Aged Mice and Obese Mice
There is at present a tremendous appetite for the development of novel pharmacological approaches to weight loss. This is in large part a response to the rising prevalence of obesity. No robustly proven answer exists as to the question of why exactly people are now becoming obese in such large numbers. There is no shortage […]
JM Smucker to spend over $120M on Hostess plant expansion
The Twinkies owner was acquired two years ago for $5.6 billion, but has since seen demand wane amid inflation and an uptick in the use of GLP-1 drugs.
Costco to sell Ozempic, Wegovy for $499 a month
Pharmaceutical company Novo Nordisk announced Friday that Costco will begin selling monthly supplies of Ozempic and Wegovy for $499 to uninsured members. The discounted price comes as more Americans have become aware of GLP-1 weight loss drugs, which have become increasingly popular as people have touted body transformations and health benefits. The popularity of the…
Costco to sell Ozempic and Wegovy at a large discount for people without insurance
Novo Nordisk, the company that makes Ozempic and Wegovy, announced Friday it will be selling the prescription injectable pens at Costco pharmacies.
Analyst Explains Why Eli Lilly (LLY) GLP-1 Advantage is Decreasing
Post Content
Obesity, diabetes, and inflammation: Pathophysiology and clinical implications
Obesity and its related disorders are now recognized as chronic inflammatory conditions. Donath and Drucker review the mechanisms underlying inflammation in these settings and discuss how understanding the mechanisms whereby Glucagon-like peptide-1 (GLP-1) receptor agonists function may unlock further therapeutic potential in chronic inflammatory diseases.